Related Experiment Video

Updated: May 12, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Glucose-6-phosphate dehydrogenase deficiency in neonatal hyperbilirubinaemia: Hacettepe experıence

H Tolga Celik1, Ceren Günbey, Sule Unal

  • 1Section of Neonatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey. htcelik@yahoo.com

Journal of Paediatrics and Child Health
|April 12, 2013
PubMed

Insights

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects 1.12% of newborns with hyperbilirubinaemia. G6PD-deficient infants showed higher rates of exchange transfusion, indicating a need for targeted G6PD testing.

Area of Science:

  • Neonatal Medicine
  • Clinical Genetics
  • Pediatric Hematology

Background:

  • Neonatal hyperbilirubinaemia is a common condition in newborns.
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic disorder affecting red blood cells.

Purpose of the Study:

  • To determine the prevalence of G6PD deficiency in neonates with hyperbilirubinaemia.
  • To compare clinical characteristics between G6PD-deficient and G6PD-normal infants.

Main Methods:

  • Retrospective evaluation of 4906 term and preterm neonates with indirect hyperbilirubinaemia.
  • Assessment of demographic data, clinical features, bilirubin levels, G6PD enzyme levels, and treatment outcomes.

Main Results:

  • G6PD deficiency was identified in 1.12% of the study population.
  • No significant differences in jaundice onset, bilirubin levels, or phototherapy duration were observed between groups.
  • G6PD-deficient infants had a significantly higher incidence of exchange transfusion (16.4% vs. 3.3%).

Conclusions:

  • G6PD deficiency testing is recommended for all newborns undergoing phototherapy, particularly those from high-prevalence regions or showing poor response to treatment.
  • Early identification of G6PD deficiency can guide management and prevent severe complications like kernicterus.
Abstract

More Related Videos

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...